ABT-724
 | |
| Identifiers | |
|---|---|
| |
| CAS Number |
70006-24-5  |
| PubChem (CID) | 5025739 |
| ChemSpider |
4204515  |
| UNII |
4WV2575JWT |
| ChEMBL |
CHEMBL440687 |
| Chemical and physical data | |
| Formula | C17H19N5 |
| Molar mass | 293.366 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
| (what is this?) (verify) | |
ABT-724 is a drug which acts as a dopamine agonist, and is selective for the D4 subtype.[1] It was developed as a possible drug for the treatment of erectile dysfunction,[2] although poor oral bioavailability means alternative drugs such as ABT-670 may be more likely to be developed commercially.[3] Nonetheless, it continues to be used in scientific research into the function of the D4 receptor.[4][5]
See also
- ABT-670
- Bremelanotide
- Cabergoline
- Flibanserin
- Intrinsa
- Melanotan II
- Pramipexole
- PF-219,061
- Tibolone
- UK-414,495
References
- ↑ Brioni JD, Moreland RB, Cowart M, Hsieh GC, Stewart AO, Hedlund P, Donnelly-Roberts DL, Nakane M, Lynch JJ, Kolasa T, Polakowski JS, Osinski MA, Marsh K, Andersson KE, Sullivan JP (April 2004). "Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats". Proceedings of the National Academy of Sciences of the United States of America. 101 (17): 6758–63. doi:10.1073/pnas.0308292101. PMC 404118
. PMID 15087502. - ↑ Cowart M, Latshaw SP, Bhatia P, Daanen JF, Rohde J, Nelson SL, Patel M, Kolasa T, Nakane M, Uchic ME, Miller LN, Terranova MA, Chang R, Donnelly-Roberts DL, Namovic MT, Hollingsworth PR, Martino BR, Lynch JJ, Sullivan JP, Hsieh GC, Moreland RB, Brioni JD, Stewart AO (July 2004). "Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction". Journal of Medicinal Chemistry. 47 (15): 3853–64. doi:10.1021/jm030505a. PMID 15239663.
- ↑ Patel MV, Kolasa T, Mortell K, Matulenko MA, Hakeem AA, Rohde JJ, Nelson SL, Cowart MD, Nakane M, Miller LN, Uchic ME, Terranova MA, El-Kouhen OF, Donnelly-Roberts DL, Namovic MT, Hollingsworth PR, Chang R, Martino BR, Wetter JM, Marsh KC, Martin R, Darbyshire JF, Gintant G, Hsieh GC, Moreland RB, Sullivan JP, Brioni JD, Stewart AO (December 2006). "Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction". Journal of Medicinal Chemistry. 49 (25): 7450–65. doi:10.1021/jm060662k. PMID 17149874.
- ↑ Newman-Tancredi A, Heusler P, Martel JC, Ormière AM, Leduc N, Cussac D (May 2008). "Agonist and antagonist properties of antipsychotics at human dopamine D4.4 receptors: G-protein activation and K+ channel modulation in transfected cells". The International Journal of Neuropsychopharmacology. 11 (3): 293–307. doi:10.1017/S1461145707008061. PMID 17897483.
- ↑ Marona-Lewicka D, Chemel BR, Nichols DE (April 2009). "Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI". Psychopharmacology. 203 (2): 265–77. doi:10.1007/s00213-008-1238-0. PMID 18604600.
This article is issued from Wikipedia - version of the 7/3/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.